ReviewTherapeutic advances in gastroenterology2019

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective.

Ágnes Milassin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.